Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-21-004397
Filing Date
2021-06-21
Accepted
2021-06-21 16:25:01
Documents
2
Period of Report
2021-06-17

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6133
2 POA cschwalmpoa.txt EX-24 3390
  Complete submission text file 0001562180-21-004397.txt   11095
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR. 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709
Business Address
Schwalm Cynthia (Reporting) CIK: 0001741455 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 211030904